On December 4, 2025, Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) released a circular outlining two key proposals for consideration at its Extraordinary General Meeting scheduled on December 19, 2025, at 2:00 p.m.

The first proposal seeks approval from independent shareholders to renew the annual caps for 2026 to 2028 under its QX001S Framework Agreement. This arrangement covers ongoing connected transactions with Zhongmei Huadong, involving product supply and a profit-sharing mechanism for SAILEXIN (QX001S). The renewed annual caps reflect anticipated production needs, market demand, and cost estimates for the next three financial years.

Additionally, the second proposal covers revisions to the company’s articles of association, aiming to update details on share capital, including the completed listing of H shares. If the recommended amendments are approved, the number of issued shares will be reflected accordingly in the articles.

Shareholders are encouraged to review the accompanying proxy form and relevant documentation. Those wishing to vote in person or by proxy must submit the necessary forms before the designated deadline. The final voting results will be released in accordance with listing rules and regulatory requirements.